<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63913">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02101437</url>
  </required_header>
  <id_info>
    <org_study_id>TCHIRB-I021003</org_study_id>
    <nct_id>NCT02101437</nct_id>
  </id_info>
  <brief_title>The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei City Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei City Hospital</source>
  <oversight_info>
    <authority>Taiwan: Ministry of Health and Welfare</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For acute coronary syndrome patients undergoing cardiac catheterization after stenting, we
      will give dual antiplatelet drugs (dual antiplatelet agents) therapy, the choice of the
      basis of medical criteria (clinical guidelines) routine as aspirin + clopidogrel or aspirin
      + ticagrelor, according to medical guidelines currently no other disposal alternative
      proposal (unless adverse drug tolerance or bleeding can not be administered); idea of ​​this
      experiment for acute coronary syndrome or conventional cardiac catheterization after
      stenting, platelet miRNA expression (miR-96 , miR-200b, miR-495, miR-107) after cardiac
      catheterization and interventional treatment of clopidogrel or ticagrelor acceptance of
      platelet reactivity (PRU) correlation values ​​(given clopidogrel or ticagrelor determined
      by the clinician, the patient follow-up experiment to track only and observation), aims to
      explore under different platelet reactivity (hyper-reactive or hypo-reactive), their
      differences in miRNA performance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>6 months.</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>PRU</condition>
  <condition>miRNA</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      miRNA in platelet(Platelet Rich Plasma)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        stable angina who received routine dual antiplatelet agents therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1 under DAPT (dual antiplatelet therapy) of stable angina patients for elective stent
        implantation.

        2. DAPT 24 hours after treatment PRU (platelet activity units) values. (Drug unresponsive
        patients was defined as PRU&gt; 235).

        Exclusion Criteria:

        1.Not suitable for the treatment of patients with DAPT. (Active peptic ulceration or
        bleeding) 2 patients of aspirin, clopidogrel, ticagrelor, cilostazol medication
        intolerance.

        3 contraindications for aspirin, clopidogrel, ticagrelor, cilostazol drug usage (such as
        heart failure patients not suitable for use cilostazol).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chen Yueh Chung, chief doctor</last_name>
    <phone>886227093600</phone>
    <phone_ext>3741</phone_ext>
    <email>chenyuehchung.tw@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei city hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Yueh Chung, chief doctor</last_name>
      <phone>886227093600</phone>
      <phone_ext>3741</phone_ext>
      <email>chenyuehchung.tw@yahoo.com.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei City Hospital</investigator_affiliation>
    <investigator_full_name>Yueh-Chung, Chen</investigator_full_name>
    <investigator_title>chief of ICU</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
